
PerkinElmer Obtains CE Mark For PKamp Respiratory SARS-CoV-2 RT-PCR Panel
On Oct. 26, 2020, PerkinElmer announced that its PKamp Respiratory SARS-CoV-2 RT-PCR Panel had received clearance to be marketed as an in vitro diagnostic device in more than 30 countries by meeting the requirements of the European In Vitro Diagnostic Directive or IVDD. The company noted that the test is currently under review by the U.S. FDA for Emergency Use Authorization or EUA.
The multi-analyte panel will enable labs to detect and differentiate between SARS-CoV-2, influenza A viruses, influenza B viruses and respiratory syncytial virus (RSV) in a single test. This is seen as critical to manage the surge in test demand during the flu season as the targeted pathogens have some similar signs and symptoms.
Instead of running multiple tests on samples, the PKamp Respiratory SARS-CoV-2 RT-PCR Panel is designed to conserve resources by testing a single nasopharyngeal, oropharyngeal or nasal swab sample collected from individuals suspected of respiratory viral infection consistent with COVID-19, the flu and RSV.
Tags:
Source: NASDAQ
Credit:
